Cure Today

Subcutaneous Opdivo Receives FDA Approval for Advanced, Metastatic Solid Tumors

Opdivo Qvantig is approved for solid tumors, including melanoma, renal cell carcinoma, and non-small cell lung cancer. The CHECKMATE-67T trial showed a 24% response rate for subcutaneous Opdivo ...
Cure Today

Subcutaneous Opdivo Similarly Effective, Safe as IV for Advanced ccRCC

Subcutaneous Opdivo showed similar efficacy and safety to intravenous Opdivo in advanced ccRCC, with a slightly higher overall response rate. The CheckMate-67T trial confirmed pharmacokinetic and ...
Healio

FDA approves Opdivo as subcutaneous injection

Please provide your email address to receive an email when new articles are posted on . Opdivo was previously only available intravenously. The approval comes after CHECKMATE-67T study results. Opdivo ...
Monthly Prescribing Reference

FDA Approves Opdivo Qvantig, a Subcutaneous Formulation of Nivolumab

The product is administered over a period of 3 to 5 minutes into the subcutaneous tissue of the abdomen or thigh by a health care provider. Opdivo Qvantig combines nivolumab, a programmed death ...
FiercePharma

Bristol Myers reveals subcutaneous Opdivo data in kidney cancer as I-O battle heads to new front

Bristol Myers Squibb is offering a detailed look at pivotal data showing that an under-the-skin version of its PD-1 inhibitor Opdivo works as well as the original intravenous formulation in kidney ...
Medical Xpress

FDA approves subcutaneous opdivo qvantig for most solid tumor indications

The U.S. Food and Drug Administration has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) injection for subcutaneous use for most previously approved adult, solid tumor Opdivo (nivolumab) ...
Seeking Alpha

New Subcutaneous Formulation of OPDIVO® Receives Positive INESSS Recommendation for Multiple Tumour Types

MONTREAL, Sept. 23, 2025 /CNW/ - Bristol Myers Squibb Canada (BMS) today announced that the Institut national d'excellence en santé et en services sociaux (INESSS) has issued a positive recommendation ...
Seeking Alpha

Bristol Myers Squibb Receives European Commission Approval for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications

Opdivo is the first and only PD-1 inhibitor approved for subcutaneous (SC) use in the European Union Approval is based on results from the Phase 3 CheckMate -67T clinical trial which demonstrated ...
Morningstar

Bristol Myers Gets CHMP Backing for Subcutaneous Opdivo

Bristol Myers Squibb said a key European regulatory committee is backing a formulation of its blockbuster cancer drug Opdivo that can be injected under the skin. Bristol Myers on Friday said the ...